CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 200-890

CHEMISTRY REVIEW(S)





NDA 200-890

Isopto[®]Carpine (pilocarpine hydrochloride ophthalmic solution) 1%, 2%, and 4%

Applicant: Alcon Research, Ltd.

Rao V. Kambhampati, Ph.D. Senior Regulatory Review Scientist Branch V Division of Pre-Marketing Assessment II ONDQA

CMC Review #2 for Division of Antiinfective and Ophthalmic Products





Table of Contents

Table of Contents 2
Chemistry Review Data Sheet3
The Executive Summary7
I. Recommendations
A. Recommendation and Conclusion on Approvability
B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable
II. Summary of Chemistry Assessments
A. Description of the Drug Product(s) and Drug Substance(s)
B. Description of How the Drug Product is Intended to be Used
C. Basis for Approvability or Not-Approval Recommendation
III. Administrative
A. Primary Reviewer
B. Secondary Reviewer
Chemistry Assessment 11
I. DRUG SUBSTANCE11
II. DRUG PRODUCT
III. INVESTIGATIONAL FORMULATIONS
IV. ENVIRONMENTAL ASSESSMENT88
V. METHODS VALIDATION88
VI. LABELING88
VII. ESTABLISHMENT INSPECTION91
VIII. DRAFT DEFICIENCY LETTER92





- 1. NDA 200-890
- 2. REVIEW #: 2
- 3. REVIEW DATE: 6-18-2010
- 4. REVIEWER: Rao V. Kambhampati, Ph.D.
- 5. PREVIOUS DOCUMENTS: None

Previous Documents

Document Date

6. SUBMISSION(S) BEING REVIEWED:

Submissions Reviewed	EDR Entry Date
Original 0000	11-23-09
Amendment 0001	11-23-09
Amendment 0002	1-21-10
Amendment 0003	2-19-10
Amendment 0004	2-8-10
Amendment 0005	3-17-10
Amendment 0006	4-16-10
Amendment 0008	5-26-10
Amendment 0009	6-16-10
Amendment 0010	6-17-10

7. NAME & ADDRESS OF APPLICANT:

Name:	Alcon Research, Ltd.
Address:	6201 South Freeway Forth Worth, TX 76134-2099
Representative:	Same as applicant
Telephone:	817-551-8120

8. DRUG PRODUCT NAME/CODE/TYPE:

- a) Proprietary Name: Isopto[®] Carpine
- b) Non-Proprietary Name: pilocarpine hydrochloride ophthalmic solution





- c) Code Name/#: AL-2910 Ophthalmic Solution
- d) Chem. Type/Submission Priority (ONDQA only):
 - Chem. Type: 3
 - Submission Priority: P
- 9. LEGAL BASIS FOR SUBMISSION: Type 505 (b)(2)
- 10. PHARMACOL. CATEGORY: Alkaloid
- 11. DOSAGE FORM: Solution
- 12. STRENGTH/POTENCY: 1% (10 mg/mL), 2% (20 mg/mL), and 4% (40 mg/mL) of pilocarpine hydrochloride.
- 13. ROUTE OF ADMINISTRATION: topical ocular
- 14. Rx/OTC DISPENSED: <u>X</u>Rx OTC
- 15. <u>SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):</u> _____SPOTS product – Form Completed

X Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, & MOLECULAR WEIGHT OF DRUG SUBSTANCE:

Chemical Name:


i) 3-Ethyldihydro-4-[(1-methyl-1*H*-imidazol-5-yl)-methyl]-2(3*H*)-furanone hydrochloride

or

ii) 2(3*H*)-Furanone, 3-ethyldihydro-4-[(1-methyl-1*H*-imidazol-5-yl)-methyl]monohydrochloride, (3S-cis)-

Established Name: Pilocarpine hydrochloride (USAN, USP, Ph Eur) Code Number/Name: AL-2910 Structural Formula:

Structural Formula:



Molecular Formula: $C_{11}H_{16}N_2O_2$. HCl





Molecular Weight: 244.72

17. RELATED/SUPPORTING DOCUMENTS: A. DMFs:

DMF Number	Holder	Description	Status	Comment
		(b) (4)	Adequate	Review #3, 6/16/10
			_	(Rao Kambhampati,
				Ph.D., ONDQA).
				Review #2, 12-20-
				96 (Allan Fenselau,
				Ph.D., ONDQA).
			Adequate	Information in NDA
				is sufficient (see
				Denise Miller's
				Product Quality
				Microbiology
				Review in
				DARRTS, 5-10-10)
			Adequate	Information in NDA
				is sufficient (see
				Denise Miller's
				Product Quality
				Microbiology
				Review in
		_		DARRTS, 5-10-10
			Adequate	Information in NDA
				is sufficient; Rao
				Kambhampati
			Adequate	Information in NDA
				is sufficient; Rao
				Kambhampati

B. Other Documents:

DOCUMENT	APPLICATION NUMBER	DESCRIPTION
Initial Quality Assessment (IQA)	200-890	Reviewed by PAL, Linda Ng,
		Ph.D., see her review in
		DARRTS.
Product Microbiology Review	200-890	Reviewed by Denise Miller,
		Ph.D., see her review in
		DARRTS. Recommendation:
		Acceptable.
Chemistry Review #3	DMF ^{(b) (4)} (Pilocarpine	Reviewed by Rao V.
-	Hydrochloride USP)	Kambhampati, see his review in
		DARRTS. Recommendation
		Adequate.
E-Mail Communication between	200-890	Entered in DARRTS by Jeannie
ONDQA PM and Alcon on 5/13/10		David, M.S., ONDQA PM





18. STATUS:

CONSULTS/CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Establishment Evaluation	Acceptable	6/16/10	E. Johnson (HFD-320, DMPQ, OC)
Product Microbiology	Acceptable	5/10/10	Denise Miller, Ph.D. (Product Microbiology Staff, OPS)
LNC	N/A (Pre-38 drug; USP Monograph)	5/13/10	Rao V. Kambhampati, Ph.D.
Proprietary Name Review	Acceptable	3/22/10	Judy Park, Carlos Mena-Grillasca, and Carol Holquist (DMEPA)
Methods Validation	Not submitted to FDA Lab per current ONDQA Policy	5/13/10	Rao V. Kambhampati, Ph.D.
EA	Categorical exclusion request acceptable	5/13/10	Rao V. Kambhampati, Ph.D.
Labeling and Container Labels	Acceptable	6/16/10	DAIOP





The Chemistry Review for NDA 200-890

Note: This is the updated final Executive Summary for this NDA

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

This NDA #200-890 provided sufficient CMC information to assure the identity, strength, purity, and quality of the drug product, therefore, from the CMC perspective this NDA is recommended for approval. The following packaging configuration was provided in the NDA:

15 mL size DROP-TAINER[®] package system containing 15-mL of 1%, 2%, or 4% strength pilocarpine hydrochloride ophthalmic solution per bottle. The recommended storage condition is store at 15° to 25°C (59° to 77°F) and protect from freezing.

1%: NDC 0998-0203-15
2%: NDC 0998-0204-15
4%: NDC 0998-0206-15

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable None

II. Summary of Chemistry Assessments

A. Description of the Drug Substances and Drug Product

<u>Introduction</u>: This is a 505 (b)(2) NDA for a pre-38 drug. The applicant received priority review status for this NDA because the drug product fulfills the unmet medical need. The active component of Isopto[®] Carpine is pilocarpine hydrochloride, which is a muscarinic cholinergic agonist. Isopto Carpine (pilocarpine hydrochloride ophthalmic solution) is a sterile, benzalkonium-preserved ophthalmic solution containing 1%, 2% or 4% of pilocarpine hydrochloride.

Isopto Carpine (pilocarpine hydrochloride ophthalmic solution) 1%, 2% and 4%, sterile topical ophthalmic drops are intended for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Isopto Carpine 1%, 2% and 4% also may be used for the treatment of acute angle-closure glaucoma, as a prophylaxis for ^{(b) (4)}





(b) (4)

post-operative elevated IOP associated with (b) (4) surgery, and

^{(b) (4)} as a potent miotic.

<u>Drug Substance</u>: The proposed drug product contains pilocarpine hydrochloride USP as the active pharmaceutical ingredient (API). Pilocarpine is an alkaloid obtained from Jaborandi leaves (*Pilocarpus microphyllus*). The CMC information for the API was cross-referenced to (^{(b) (4)}) which was reviewed previously and found to be adequate (12/20/96).

which was reviewed previously and found to be adequate (12/20/96)by Allan Fenselau, Ph.D. (Chemist, ONDQA). Since then an amendment and annual reports were submitted to this DMF and they were reviewed by this reviewer and the DMF is still adequate. On the basis of DMF Holder's drug substance specification, Alcon initially proposed ^{(b) (4)} content in the NDA drug an acceptance criterion (AC) of NMT substance specification. However, since the drug product will be used as an ophthalmic, Alcon ^{(b) (4)}. Initially Alcon was unable to tighten the AC was asked to tighten the AC for "". Therefore, we negotiated with (b) (4) directly and because of disagreement with $^{(b)}$ (4) agreed to tighten the AC to in the 6/14/10 teleconference, , which is acceptable to us. Pilocarpine hydrochloride is manufactured by

^{(b) (4)} and supplied to the Applicant. Alcon also conducts testing of the drug substance and their specification was provided in the NDA. The initially proposed specification did not include microbial limits test, however, upon comment the applicant agreed to include it (b) (4) and the results are in the specification indicating that the test is performed by ^{(b)(4)} Batch analysis results were provided for three batches and the obtained from ^{(b) (4)} by the titration method. The total impurities content assay values ranged from ^{(b) (4)} It was demonstrated that the drug substance can be manufactured with consistent was quality and purity. In the batch analysis table, the impurities were shown as NMT of a certain $\frac{(b)}{(b)}$ contained the actual percentages, therefore, the percentage, however, applicant was asked to include the actually observed values in the batch analysis table. In the email communication (5/13/10) and later in the amendment dated 5/26/10, the applicant provided revised batch analysis tables containing the actually observed values. The drug $^{(b)}$ bags and then placed in substance is packaged in sealed drums ^{(b) (4)} stability studies on three batches at and closed with LDPE caps. Based on the ^{(b) (4)} for the drug 30±2°C and 75±5% humidity, the applicant assigned a shelf-life of substance.

Drug Product:

The proposed drug product, Isopto[®] Carpine (pilocarpine hydrochloride ophthalmic solution) is a sterile, preserved ophthalmic solution containing either 1% (10 mg/mL), 2% (20 mg/mL), or 4% (40 mg/mL) of pilocarpine hydrochloride as the active ingredient. It is manufactured at the Applicant's facility in Forth Worth, TX. The drug product is packaged in a plastic bottle with a plastic dispensing plug and plastic closure. The excipients include boric acid, sodium chloride (1% strength only), sodium citrate, dihydrate, benzalkonium chloride (preservative), hypromellose 2910 (HPMC), hydrochloric acid and/or sodium hydroxide (for pH adjustment), and purified water. The API is USP grade and all excipients are USP/NF grade. The proportions of the excipients (boric acid, sodium chloride, and sodium citrate, dihydrate) in the three strengths are slightly different. The applicant initially requested an overage of (b) (4) for the all three strengths. However, upon comment, the ^{(b) (4)} overage was withdrawn for the 1% strength, and adequate justification for 2% and 4% strengths was provided in the e-mail communication dated 5-13-10 and later in the amendment dated 5/26/10. Since this product has been marketed for several years, the applicant did not conduct much pharmaceutical (b) (4) development. The manufacturing process consists of





^{(b) (4)} The batch formula was provided for the full production scale batch of ^{(b) (4)} The drug product specification included identity by HPLC and TLC, assay by HPLC, impurities by HPLC, benzalkonium chloride (preservative) identity and assay by HPLC, pH, osmolality, color, clarity, viscosity, particulate matter, bacterial endotoxins, and sterility. Upon comment, the acceptance criteria for impurities were tightened for ^{(b) (4)} and total impurities. Adequate description

was provided for the Alcon analytical procedures and the particulate matter test is conducted as according to USP <789>. Analytical method validation reports were provided for pilocarpine hydrochloride identity, assay, and degradation products by HPLC method, identity by TLC method, benzalkonium chloride identity and assay by HPLC method, bacterial endotoxins, sterility, and antimicrobial effectiveness methods. The reports are acceptable. Batch analyses results were provided for three batches for each strength. The data demonstrated that the drug product can be manufactured with consistent quality and purity. The assay values ranged from

^{(b) (4)} and the total impurities content ranged from ^{(b) (4)} Stability study results were provided for three batches of all three strengths. The studies were conducted in the proposed commercial container/closure at 25°C/40% RH. Stability data for 36 months were provided for two batches and 24 months data were provided for one batch. There was no significant change in the assay values. However, there was an increase of ^{(b) (4)}

, and total impurities. According to the literature, this drug product is expected to produce these impurities upon storage. All results are within the proposed specification for the drug product. Based on the real time stability data, the proposed expiration dating period of 36 months is acceptable. The applicant requested a storage condition of the applicant was asked to change the storage condition to 15°-25°C with protection from freezing. Since the stability data contained testing points for 12, 24, and 36 months only, the applicant was also asked to study the next three annual commercial batches using the ICH recommended testing points.

B. Description of How the Drug Product is Intended to be Used

In the revised package insert (6/15/10), it was stated that the Isopto® Carpine is a muscarinic cholinergic agonist indicated for the following: i) The reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; ii) The management of acute angle-closure glaucoma; iii) The prevention of postoperative elevated IOP associated with laser surgery; and iv) The induction of miosis. The drug product is manufactured in three strengths, 1% (10 mg/mL), 2% (20 mg/mL), and 4% (40 mg/mL) of pilocarpine hydrochloride. One drop of the solution is instilled in the eye (s) up to four times daily. Isopto[®] Carpine (pilocarpine hydrochloride ophthalmic solution) 1%, 2% and 4% is supplied sterile in 15 mL natural LDPE plastic ophthalmic DROP-TAINER® dispensers containing 15 mL of the solution with appropriate color-coding (green LDPE tips and green polypropylene caps).

It is stored at 15° to 25°C (59° to 77°F) and protected from freezing.

C. Basis for Approvability or Not-Approval Recommendation

The applicant proposed to use the drug substance (pilocarpine hydrochloride USP) from the same source (b) (4) which is supplying the same drug substance for the manufacturing of (b) (4) The drug substance is manufactured

according to the process in the DMF ^{(b) (4)} which has been reviewed and found to be adequate. It was demonstrated that the drug product solution can be manufactured and packaged with





consistent quality and purity and it can be stored at 25°C. Adequate in-process controls are in place during various stages of the manufacturing and packaging processes. The review of the NDA from product quality microbiology stand point is acceptable. The drug substance $(\tilde{b})^{(4)}$ the drug product manufacturing and packaging manufacturing facility facility (Alcon, Ft. Worth, TX), and the testing facilities are acceptable and an Overall Acceptable Recommendation was issued by the Office of Compliance. The trademark, Isopto[®] Carpine, was found to be acceptable by DMEPA. Per current ONDQA policy, this drug product does not require analytical method validation by the FDA laboratory. The applicant satisfactorily addressed all the comments and recommendations in the IR letters dated 3/19/10, 5/7/10, and 5/25/10. The draft responses to the 5/7/10 IR letter were initially provided by email communication to the ONDQA Project Manager and later the final responses were provided in the 5/25/10 amendment. Comments on the draft package insert and container and carton labels were communicated to the clinical reviewer (William Boyd, M.D., DAIOP) and the revised PI and container/carton labels (6/15/10) contained the suggested changes. Categorical exclusion from the requirement from preparing EA for the NDA for the proposed drug product is acceptable because the drug has already been marketed in the US for over 40 years, therefore, it will not increase the use of active moiety if this NDA is approved. Therefore, from the CMC stand point this NDA #200-890 is recommended for approval.

III. Administrative

A. Primary Reviewer:

Rao V. Kambhampati, Ph.D. Senior Regulatory Review Scientist Branch V, DPA II, ONDQA, OPS

B. Secondary Reviewer:

Stephen P. Miller, Ph.D. Acting Chief, Branch V, DPA II, ONDQA, OPS

84 Pages has been withheld in full immediately following this page as B4 (CCI/TS)

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-200890	ORIG-1	ALCON INC	PILOCARPINE

HYDROCHLORIDE OPHTHALMIC SOLUTION, 1%, 2% AND 4%

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

RAO V KAMBHAMPATI 06/18/2010

STEPHEN P MILLER 06/18/2010 I concur - approval of this NDA is recommended from the CMC perspective





NDA 200-890

Isopto[®]Carpine (pilocarpine hydrochloride ophthalmic solution) 1%, 2%, and 4%

Applicant: Alcon Research, Ltd.

Rao V. Kambhampati, Ph.D. Senior Regulatory Review Scientist Branch IV Division of Pre-Marketing Assessment II ONDQA

CMC Review #1 for Division of Antiinfective and Ophthalmic Products





Table of Contents

Table of Contents
Chemistry Review Data Sheet
The Executive Summary
I. Recommendations
A. Recommendation and Conclusion on Approvability
B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable
II. Summary of Chemistry Assessments
A. Description of the Drug Product(s) and Drug Substance(s)
B. Description of How the Drug Product is Intended to be Used
C. Basis for Approvability or Not-Approval Recommendation
III. Administrative
A. Primary Reviewer
B. Secondary Reviewer
Chemistry Assessment
I. DRUG SUBSTANCES
II. DRUG PRODUCT
III. INVESTIGATIONAL FORMULATIONS
IV. ENVIRONMENTAL ASSESSMENT
V. METHODS VALIDATION
VI. LABELING
VII. ESTABLISHMENT INSPECTION
VIII. DRAFT DEFICIENCY LETTER





- 1. NDA 200-890
- 2. REVIEW #: 1
- 3. REVIEW DATE: 5-14-2010

4. REVIEWER: Rao V. Kambhampati, Ph.D.

4. PREVIOUS DOCUMENTS: None

Previous Documents

Document Date

4. SUBMISSION(S) BEING REVIEWED:

Submissions Reviewed	eCTD Entry Date	EDR Date
Original 0000	11-23-09	
Amendment 0001	11-23-09	
Amendment 0002	1-21-10	
Amendment 0003	2-19-10	
Amendment 0004	2-8-10	
Amendment 0005	3-17-10	
Amendment 0006	4-16-10	
E-Mail Communication	5-13-10	
between ONDQA PM and		
Alcon		


7. NAME & ADDRESS OF APPLICANT:

Name:	Alcon Research, Ltd.
Address:	6201 South Freeway Forth Worth, TX 76134-2099
Representative:	Same as applicant
Telephone:	817-551-8120

8. DRUG PRODUCT NAME/CODE/TYPE:

- a) Proprietary Name: Isopto[®] Carpine
- b) Non-Proprietary Name: pilocarpine hydrochloride ophthalmic solution







c) Code Name/#: AL-2910 Ophthalmic Solution

- d) Chem. Type/Submission Priority (ONDQA only):
 - Chem. Type: 3
 - Submission Priority: P
- 9. LEGAL BASIS FOR SUBMISSION: Type 505 (b)(2)
- 10. PHARMACOL. CATEGORY: Alkaloid
- 11. DOSAGE FORM: Solution
- 12. STRENGTH/POTENCY: 1%, 2%, and 4%
- 13. ROUTE OF ADMINISTRATION: topical ocular
- 14. Rx/OTC DISPENSED: <u>X</u> Rx OTC
- 15. <u>SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):</u> <u>X</u>SPOTS product – Form Completed Yes

____Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:


Chemical Name:

i) 3-Ethyldihydro-4-[(1-methyl-1*H*-imidazol-5-yl)-methyl]-2(3*H*)-furanone hydrochloride

or

ii) 2(3*H*)-Furanone, 3-ethyldihydro-4-[(1-methyl-1*H*-imidazol-5-yl)-methyl]monohydrochloride, (3S-cis)-

Established Name: Pilocarpine hydrochloride (USAN, USP, Ph Eur) Code Number/Name: AL-2910 Structural Formula:



Molecular Formula: C₁₁H₁₆N₂O₂ · HCl Molecular Weight: 244.72





17. RELATED/SUPPORTING DOCUMENTS: A. DMFs:

DMF Number	Holder	Description	Status	Comment
		(b) (4)	Adequate	Reviewed by Allan
				Fenselau, Ph.D.
				(ONDQA). Minor
				amendments were
				submitted
				afterwards and they
				are acceptable; Rao
				Kambhampati.
			Adequate	Information in NDA
				is sufficient (see
				Denise Miller,
				Product Quality
				Microbiology
				Review in
			A 1 (DARRTS, 5-10-10)
			Adequate	Information in NDA
				is sufficient (see
				Denise Miller, Product Quality
				Product Quality Microbiology
				Review in
				DARRTS, 5-10-10
			Adequate	Information in NDA
			Aucquaic	is sufficient; Rao
				Kambhampati
			Adequate	Information in NDA
			1 acquate	is sufficient; Rao
				Kambhampati
				ixumonumpun

B. Other Documents:

DOCUMENT	APPLICATION NUMBER	DESCRIPTION
Initial Quality Assessment (IQA)	200-890	Reviewed by PAL, Linda Ng,
		Ph.D., see her review in
		DARRTS.
Product Microbiology Review	200-890	Reviewed by Denise Miller,
		Ph.D., see her review in
		DARRTS. Recommendation:
		Acceptable.

18. STATUS:

CONSULTS/CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
Establishment Evaluation	Pending	5/13/10	(HFD-320, DMPQ, OC)
Product Microbiology	Acceptable	5/10/10	Denise Miller, Ph.D. (Product





			Microbiology Staff, OPS)
LNC	N/A (Pre-38 drug; USP	5/13/10	Rao V. Kambhampati, Ph.D.
	Monograph)		
Proprietary Name Review	Acceptable	3/22/10	Judy Park, Carlos Mena-Grillasca, and
			Carol Holquist (DMEPA)
Methods Validation	Not submitted to FDA Lab	5/13/10	Rao V. Kambhampati, Ph.D.
	per current ONDQA Policy		
EA	Categorical exclusion request	5/13/10	Rao V. Kambhampati, Ph.D.
	acceptable		
Labeling and Container	Pending	5/13/10	DAIOP
Labels			





The Chemistry Review for NDA 200-890

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

At this point, this NDA did not provide sufficient CMC information to assure the identity, strength, purity, and quality of the drug product. The following issues need to be resolved:

- Package Insert and Container and Carton labeling
- Overall site recommendation from the Office of Compliance
- Tightening of the acceptance criterion for (b) (4) content in the drug substance specification from the current (b) (4)

Therefore, from the CMC perspective, this NDA is not recommended for approval as of this date. The following packaging configuration was provided in the NDA:

15 mL size DROP-TAINER[®] package system containing 15-mL of 1%, 2%, or 4% strength pilocarpine hydrochloride ophthalmic solution per bottle.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable None

II. Summary of Chemistry Assessments

A. Description of the Drug Substances and Drug Product

Introduction: This is a 505 (b)(2) NDA for a pre-38 drug. The applicant received priority review status for this NDA because the drug product fulfills the unmet medical need. The active component of Isopto[®] Carpine is pilocarpine hydrochloride, which is a muscarinic cholinergic agonist. Isopto Carpine (pilocarpine hydrochloride ophthalmic solution) is a sterile, benzalkonium-preserved ophthalmic solution containing 1%, 2% or 4% of pilocarpine hydrochloride.

Isopto Carpine (pilocarpine hydrochloride ophthalmic solution) 1%, 2% and 4%, sterile topical ophthalmic drops are intended for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Isopto Carpine 1%, 2% and 4% also may be used for the treatment of acute angle-closure glaucoma, as a prophylaxis for post-operative elevated IOP associated with ^{(b) (4)} surgery, and ^{(b) (4)} as a potent miotic.





<u>Drug Substance</u>: The proposed drug product contains pilocarpine hydrochloride as the pharmaceutical active ingredient (PAI). The CMC information for the API was cross-referenced to the DMF^{(b)(4)} which was reviewed by Allan Fenselau, Ph.D. (Chemist, ONDQA) and determined to be acceptable. The applicant also provided some CMC information directly in the NDA. Pilocarpine is an alkaloid obtained from Jaborandi leaves (*Pilocarpusmicrophyllus*). It is manufactured by

and supplied to the Applicant. Alcon also conducts testing of the drug substance and their specification was provided in the NDA. The initially proposed specification did not include microbial limits test, however, upon comment the applicant agreed to include it in the specification indicating that the test is performed by the results are obtained from ^{(b) (4)}. Since the drug substance is used for the formulation of ophthalmic solution, the Applicant was asked to tighten the acceptance criterion from the current NMT ^{(b) (4)} (reported batches range from NMT ^(b) (4)</sup>

(b) (4) Batch analysis results were provided for three batches and the assay values ranged from (b) (4) by the titration method. The total impurities content was (b) (4) It was demonstrated that the drug substance can be manufactured with consistent quality and purity. In the batch analysis table the impurities were shown as NMT of a certain percentage, however, (b) (4) contained the actual percentages, therefore, the applicant was asked to include the actually observed values in the batch analysis table. In the e-mail (5/13/10) communication, the applicant provided revised batch analysis tables containing the actually observed values. The drug substance is packaged in sealed (b) (4) bags and then placed in (b) (4) drums and closed with LDPE caps. Based on the (b) (4) stability studies on three batches at 30±2°C and 75±5% humidity, the applicant assigned a shelf-life of (b) (4) for the drug substance which is adequately supported by the data.

Drug Product:

The proposed drug product, Isopto[®] Carpine (pilocarpine hydrochloride ophthalmic solution) 1%, 2% and 4% is a sterile, preserved ophthalmic solution containing either 1%, 2% or 4% of pilocarpine hydrochloride as the active ingredient. It is manufactured at Applicant's facility in Forth Worth, TX. The drug product is packaged in a plastic bottle with a plastic dispensing plug and plastic closure. The excipients include boric acid, sodium chloride (1% strength only), sodium citrate, dihydrate, benzalkonium chloride (preservative), hypromellose 2910 (HPMC), hydrochloric acid and/or sodium hydroxide (for pH adjustment), and purified water. The API is USP grade and all excipients are USP/NF grade. The proportions of the excipients (boric acid, sodium chloride, and sodium citrate, dihydrate) in the three strengths are slightly different. The applicant initially requested an overage of ^{(b)(4)} for the API, however, upon comment, the ^{(b)(4)} overage was requested for the 2% and 4% strengths only by providing adequate justification in the e-mail communication dated 5-13-10. Since this product has been marketed for several years, the applicant did not conduct much pharmaceutical development. The manufacturing process consists of

The batch formula was provided for the full production scale batch of ^{(b) (4)} The drug product specification included identity by HPLC and TLC, assay by HPLC, impurities by HPLC, benzalkonium chloride (preservative) identity and assay by HPLC, pH, osmolality, color, clarity, viscosity, particulate matter, bacterial endotoxins, and sterility. Upon comment, the acceptance criteria for impurities were tightened for ^{(b) (4)} acceptance criterion cannot be tightened at this point because it is same as for the drug substance. Adequate description was provided for the all Alcon analytical procedures and the particulate matter test is conducted as



according to USP <789>. Analytical methods validation reports were provided for pilocarpine hydrochloride identity, assay, and degradation products by HPLC method, identity by TLC method, benzalkonium chloride identity and assay by HPLC method, bacterial endotoxins, sterility, and antimicrobial effectiveness methods. The reports are acceptable. Batch analyses results were provided for three batches for each strength. The data demonstrated that the drug product can be manufactured with consistent quality and purity. Initial batch analysis results did not contain the actually observed results for the impurities, however, upon comment they were incorporated in the revised batch analysis tables. The assay values ranged from ^{(b) (4)}

^{(b) (4)} Stability study results were and the total impurities content ranged from provided for three batches of all three strengths. The studies were conducted in the proposed commercial container/closure at 25°C/40%RH. Stability data for 36 months were provided for two batches and 24 months data were provided for one batch. There was no significant change (b) (4), and total in the assay values. However, there was an increase of impurities. According to the literature, this drug product is expected to produce these impurities upon storage. All results are within the proposed specification for the drug product. Based on the real time stability data, the proposed expiration dating period of 36 months is acceptable. ^{(b) (4)} however, since no stability data were The applicant requested a storage condition of provided for the refrigerated condition, the applicant was asked to change the storage condition to 15°-25°C with protection from freezing. Since the stability data contained testing points for 12, 24, and 36 months only, the applicant was also asked to study the next three annual commercial batches using the ICH recommended testing points.

B. Description of How the Drug Product is Intended to be Used

Isopto® Carpine is a muscarinic cholinergic agonist indicated for the following: i) open-angle glaucoma or ocular hypertension; ii) acute angle-closure glaucoma; iii) prevention of postoperative elevated IOP; and iv) induction of miosis. The drug product is manufactured in three strengths, 1%, 2%, and 4% and each mL of these solutions contains 10 mg, 20 mg, and 40 mg of pilocarpine hydrochloride, respectively. One to two drops of the solution is instilled in the eye (s) up to four times daily. Isopto[®] Carpine (pilocarpine hydrochloride ophthalmic solution) 1%, 2% and 4% is supplied sterile in 15 mL natural LDPE plastic ophthalmic DROP-TAINER® dispensers containing 15 mL of the solution with green LDPE tips and green polypropylene caps as follows:

1%: NDC 0998-0203-15 2%: NDC 0998-0204-15 4%: NDC 0998-0206-15


It is stored at 15° to 25°C (59° to 77°F) and protected from freezing.

C. Basis for Approvability or Not-Approval Recommendation

The applicant proposed to use the drug substance (pilocarpine hydrochloride) from the same source $(b)^{(4)}$ which is supplying the same drug substance for the manufacturing of $(b)^{(4)}$

⁽⁴) . The drug substance is manufactured as according to the process in the DMF ^{(b) (4)} which was reviewed previously by the FDA chemist and found to be adequate. It was demonstrated that the drug product solution can be manufactured and packaged with consistent quality and purity and it can be stored at 25°C. Adequate in-process controls are in place during various stages of the manufacturing and packaging processes. The review of the NDA from product quality microbiology stand point is acceptable. The







(b) (4) is pending inspection status of the drug substance manufacturing facility and the drug product manufacturing and packaging facility (Alcon, Ft. Worth, TX) was found to be acceptable on the basis of the file review by the OC. The trademark, Isopto[®] Carpine, was found to be acceptable by DMEPA. Per current ONDQA policy, this drug product does not require analytical method validation by the FDA laboratory. The applicant satisfactorily addressed all the comments and recommendations in the IR letters dated 3/19/10 and 5/7/10 ^{(b) (4)} content in the drug substance specification. The responses to except tightening of the the 5/7/10 IR letter were provided by e-mail communication to the ONDQA Project Manager. Comments on the draft package insert and container and carton labels were communicated to the clinical reviewer (William Boyd, M.D., DAIOP). Per DIAOP's practice, comments from all disciplines will be incorporated in the draft labeling documents and then they will be communicated to the applicant for their incorporation in the final labeling documents. Therefore, the package insert and container and carton labels are pending as of this date. Categorical exclusion from the requirement of preparing EA for the NDA for the proposed drug product is acceptable because the drug has already been marketed in US for over 40 years, therefore, it will not increase the use of active moiety if this NDA is approved. Because of the pending CMC, inspectional, and labeling issues, this NDA cannot be approved at this time.

III. Administrative

A. Primary Reviewer:

Rao V. Kambhampati, Ph.D. Senior Regulatory Review Scientist Branch IV, DPA II, ONDQA, OPS

B. Secondary Reviewer:

Stephen P. Miller, Ph.D. Acting Chief, Branch IV, DPA II, ONDQA, OPS

83 Pages has been withheld in full immediately following this page as B4 (CCI/TS)

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-200890	ORIG-1	ALCON INC	PILOCARPINE

HYDROCHLORIDE OPHTHALMIC SOLUTION, 1%, 2% AND 4%

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

RAO V KAMBHAMPATI 05/14/2010

STEPHEN P MILLER 05/14/2010 I concur - from the CMC perspective we cannot recommend approval at this time

Initial Quality Assessment Branch __IV__ Pre-Marketing Assessment Division __II__

OND Division:	Division of Anti-Infective and Ophthalmology Produ
NDA:	200-890
Applicant:	Alcon Research Ltd
Stamp Date:	December 22, 2009
PDUFA Date:	June 22, 2010
Trademark:	Isopto Carpine
Established Name:	(pilocarpine hydrochloride ophthalmic solution) 1%,
	2% and 4%
Dosage Form:	Ophthalmic Solution
Route of Administration:	Topical
Indication:	Treatment of various IOP indications

PAL: Linda Ng, Ph.D.

	YES	NO
ONDQA Fileability:	\boxtimes	
Comments for 74-Day Letter		\boxtimes

Summary and Critical Issues:

Summary

This NDA, 3S, dated December 22, 2009, is an ophthalmic solution compared to the approved ophthalmic gel 4% in NDA 18-796. The product is a self preserved multi-use ophthalmic solution in 3 strengths for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, (b) (4) postoperative elevated IOP

associated with (b)(4) laser surgery, and (b)(4) laser surgery (b)(4) associated with (b

(b) (4) as a potent miotic. This is a 505(b) (4) NDA, submitted in eCTD format and was accepted for priority review. The trade name is the same as the one marketed in the US without approval.

A microbiology consult was submitted by the OND PM, Lori Gorski and Dr. Denise Miller was assigned. The trade name consult was sent directly from the applicant to OSE. The EES evaluation was performed by ONDQA PM Jeannie David who confirmed sites with the applicant and finalized the request with the CMC reviewer Rao Kambhampati.

The drug substance, pilocarpine hydrochloride is manufactured by (b) (4) (b) (4) Pilocarpine is an alkaloid extracted from Jaboradni leaves (*Pilocarpus*

microphyllus) and acidified. An LOA dated December 8, 2009 was submitted, referencing the synthesis, controls and stability information to DMF^{(b)(4)}. The drug substance and drug product USP monographs are available. Information is also available in *Analytical Profiles of Drug Substances and Excipients*. The applicant claims that Pilocarpine has been marketed for more


than 50 years in the US. The compound is claimed to be very stable with a retest period of proposed.

The drug product has ^{(b) (4)} a preservative. ^{(b) (4)} in the stability of the product. Thus the product is maintained at pH range of 3.5 to 5.5. The product is manufactured, packaged, labeled, release and stability tested at Alcon's ASPEX facility in Fort Worth, Texas.

The drug product is stored in Alcon's natural LDPE 'Drop-tainer" bottle, green LDPE plug, and a green polypropylene cap with pressure sensitive label and shrink band around the neck and cap. The container and plug resins are described in DMF^{(b)(4)} and the cap resin, ^{(b)(4)} is in DMF^{(b)(4)}. ^{(b)(4)} referenced in DMF^{(b)(4)} sterilization, DMF^{(b)(4)}, is the sterilization technique is used for the closures; and ^{(b)(4)} sterilization, DMF^{(b)(4)} for the bottles and plugs. The trade sample is a 15 mL fill in a 15 mL bottle. No professional sample size proposed.

The batch size is claimed to be ^{(b) (4)}. The stability data were generated using 3 batches at each strength, with horizontal position (claimed worst position), and ^{(b) (4)} size. For each strength, two batches for 36 months and 1 batch for 24 months data are provided. An expiry of 36 months is claimed. Product is claimed to be stored between ^{(b) (4)}

Structural Formula:



Molecular Formula: C11H16N2O2 HCl

Molecular Weight: 244.72

Critical issues for review

- This is a SPOT product and should be entered in database.
- All tests should be evaluated for meaningful conditions and criteria for both drug substance and drug product. In the drug substance specification, values should be reported instead of "NMT^{(b) (4)} and microbial limits may need to be included. In the drug product, the endotoxin level is expressed on a per dose basis that converts to ^{(b) (4)} per mL. This is higher than products approved in the past. Micro will have to evaluate.

NDA 200-890 CMC IQA Review

•

- Osmolality in the drug product specification is set between ^{(b) (4)}. The
- 1% and 2% have lower upper limit. The range seems large for the 4% and reviewer should evaluate need for this wide acceptance criterion.
- In the drug product specification, any individual unspecified impurity should be set at NMT than ^{(b) (4)}.
- The applicant claims to monitor substance specification only indicates test for Reviewer should evaluate for contradiction.
 (b) (4) as residual solvents, but the drug (b) (4).
 (b) (4) is used in late stages.
- The overage is claimed to should evaluate need. Overage is not granted for (b) (4) Reviewer
- An average drop size study seems to be missing. Also not claimed is a physician sample size.
- The ^{(b) (4)} information appears to be missing. Reviewer should follow up.
- Molecular formula seems to be missing in the description of the package insert. Also missing is the fill size in the How Supplied. The storage room temperature should not start at ^{(b) (4)}.
- The preservative effectiveness test is missing in the drug product specification. Micro should be alerted to evaluate. If a study to support the preservative, benzalkonium chloride is effective, it is acceptable to drop the preservative effectiveness test in the specification.

• Comments for 74-Day Letter

None recommended.

D. Review, Comments and Recommendation:

Acceptable for filing. Dr. Rao Kambhampati has been assigned to review this NDA.

____Linda Ng, Ph.D.____ Pharmaceutical Assessment Lead

Date

____Stephen Miller, Ph.D.____ Acting Branch Chief

Date

Cc: OND PM LGorshi ONDQA PM JDavid

Appendix 1. **Composition of the Drug Product**

	Concentration (%w/v)				
Component	Isopto Carpine 1%ª	Isopto Carpine 2% ^b	Isopto Carpine 4% ^c	Function	Compendial Status
Pilocarpine hydrochloride	1.0 ^d	2.0 ^d	4.0 ^d	Active Ingredient	USP
Boric acid				(b) (4)	NF
Sodium chloride				_	USP
Sodium citrate, dihydrate					USP
Benzalkonium chloride	0.01	0.01	0.01	Preservative	NF
Hypromellose 2910 (HPMC)				(b) (4)	USP
Hydrochloric Acid			(b) (4)		NF
and/or				pH Adjustment	
Sodium Hydroxide					NF
Purified Water				(b) (4)	USP

Table 2.3.P.1–1 Composition of ISOPTO Carpine 1%, 2% and 4%

^a Formulation ID No. 10026; ^b Formulation ID No. 11631; ^c Formulation ID No. 99222; ^d Up to ^{(b) (4)} overage may be added to ^{(b) (4)}

2 page(s) have been Withheld in Full immediately following this page as B4 (CCI/TS)

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-200890	ORIG-1	ALCON INC	PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION, 1%, 2% AND 4%

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

------/s/

LINDA L NG

02/19/2010

STEPHEN P MILLER 02/23/2010

NDA FILEABILITY CHECKLIST

NDA Number: 200890 Applicant: Alcon Research Ltd Letter Date: December 22, 2009 Stamp Date: December 22, 2009 Drug Name: Isopto Carpine (pilocarpine hydrochloride Ophthalmic Solution) 1, 2 and 4%

IS THE CMC SECTION OF THE APPLICATION FILEABLE? (Yes or No) <u>Yes</u>

The following parameters are necessary in order to initiate a full review, i.e., complete enough to review but may have deficiencies.

	Parameter	Yes	No	Comment
1	On its face, is the section organized adequately?	Y		
2	Is the section indexed and paginated adequately?	Y		This is an eCTD NDA
3	On its face, is the section legible?	Y		
4	Are ALL of the facilities (including contract facilities and test laboratories) identified with full street addresses and CFNs?	Y		Not complete CFN list
5	Is a statement provided that all facilities are ready for GMP inspection?	Y		In cover letter
6	Has an environmental assessment report or categorical exclusion been provided?	Y		1.12.14
7	Does the section contain controls for the drug substance?	Y		Pilocarpine HCl supplied by (b) (4)
8	Does the section contain controls for the drug product?	Y		
9	Has stability data and analysis been provided to support the requested expiration date?	Y		Three strengths @ 1, 2 and 4%. All 15 mL fill size in 15 mL bottles. 2 batches each strength at 36 months and 1 batch each at 24 months stability RT horizontal only provided.
10	Has all information requested during the IND phase, and at the pre-NDA meetings been included?		N	Product marketed over 40 years in the US without approval
11	Have draft container labels been provided?	Y		Mock-up provided for all three strengths
12	Has the draft package insert been provided?	Y		
13	Has an investigational formulations section been provided?		N	Product marketed over 40 years in the US without approval
14	Is there a Methods Validation package?		Ν	Information found in 3.2.P.5.3
15	Is a separate microbiological section included?		N	Incorporated in the CMC section

NDA 200-890

Chemistry Reviewer: Pharmaceutical Assessment Lead: Branch Chief: Prepared by: LN 1/21/10 Rao Kambhampati, Ph.D. Linda Ng, Ph.D. Stephen Miller, Ph.D.

DMF Number	Holder	Description	LOA Included	Status
1		(b) (4	December 8, 2009	
			May 20, 2008	
			May 11, 2009	
			November 24, 2009	
			February 15, 2008	

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-200890	ORIG-1	ALCON INC	PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION, 1%, 2% AND 4%

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

------/s/

LINDA L NG 01/22/2010

STEPHEN P MILLER 01/22/2010